UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

Teva Pharmaceuticals is suing the Centers for Medicare & Medicaid Services (CMS) for its implementation of the drug price ...

Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...

The following is a summary of “Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program,” ...

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to ...

Teva Pharmaceuticals has announced a strategic ... which will be sold under the brand name AHZANTIVE®, pending regulatory approval. Klinge, which holds the global commercialization rights ...

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...

In this article, we are going to take a look at where Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) stands against the other stocks. The stock market finished the first trading day of the year ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...